Generics BulletinAmgen is trying to gain traction for its Pavblu (aflibercept-ayyh) biosimilar purely by offering better financial incentives, according to Eylea (aflibercept) originator Regeneron, which is continuing
ScripMerck & Co. could have an edge in the cholesterol market with the first oral PCSK9 inhibitor. The company announced positive topline data on June 9 from the first two Phase III trials testing enli
Pink SheetThe Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai
ScripVigil Neuroscience’s TREM2 agonist iluzanebart failed in a Phase II study for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and deadly neurod